Table 1.

Clinical characteristics of the children with T. marneffei

Clinical characteristics	Cases (N = 21)
Demographics
Age (months), median (IQR)	22 (15–34)
Gender, male (%)	15 (71.43)
Endemic area, No(%)	21 (100.00)
Month of diagnosis, median (IQR)	7 (4–9)
Signs and Symptoms
The interval from onset to addmission (days), median (IQR)a	20 (12–30)
Fever, No. (%)	20 (95.24)
Cough, No. (%)	17 (80.95)
Hepatomegaly, No. (%)	17 (80.95)
Lymphadenopathy, No. (%)	15 (71.43)
Splenomegaly, No. (%)	12 (57.14)
Skin lesion, No. (%)	9 (42.86)
Dyspnea, No. (%)	9 (42.86)
Diarrhea, No. (%)	6 (28.57)
Weight loss, No. (%)	6 (28.57)
Malnutrition, No. (%)	4 (19.09)
Ascites, No. (%)	1 (4.76)
Trachyphonia, No. (%)	1 (4.76)
Significant complication
Sepsis shock, No. (%)	12 (57.14)
HLH, No. (%)	11 (52.38)
ARDS, No. (%)	10 (47.62)
MODS, No. (%)	9 (42.86)
DIC, No. (%)	7 (33.33)
Specimens for diagnosis
Blood, No(%)	19 (90.48)
BM, No(%)	8 (38.10)
Lymph nodes, No(%)	4 (19.09)
Airway mucosal biopsy, No(%)	2 (9.52)
BALF, No(%)	2 (9.52)
Ascites, No(%)	1 (4.76)
Skin, No(%)	1 (4.76)
Stool, No(%)	1 (4.76)
Antifungal therapy
The interval from onset to antifungal therapy (days), median (IQR)	25 (17.5–31.5)
Total, No(%)	19 (90.48)
Amphotericin B, No(%)	8 (38.10)
Voriconazole, No(%)	8 (38.10)
Itraconazole, No(%)	6 (28.57)
Fluconazole, No(%)	5 (23.81)
Caspofungin, No(%)	3 (14.29)
Outcomes
Length of stay (days), median (IQR)	14.5 (4–31)
Mortality, No. (%)	11 (52.38)

Abbreviation: ARDS acute respiratory distress syndrome, MODS multiple organ dysfunction syndrome, HLH hemophagocytic lymphohistiocytosis, DIC disseminated intravascular coagulation, BM bone marrow, BALF bronchial alveolar lavage fluid, IQR: inter-quartile range

^aThe course of disease before addmission at our hospital